The emergence of AI, notably in the field of drug discovery, is reshaping the future of medicine The emergence of artificial intelligence (AI), notably in the field of drug discovery, is reshaping

The recent surge in activity in deploying AI capabilities in pharmaceutical R&D shows no sign of abating, with ‘big pharma’ investing significant capital in streamlining or accelerating the drug discovery

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost

Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, announces a significant breakthrough in its world first influenza Artificial Intelligence (‘AI’)

Using an AI platform developed by CytoReason, London-headquartered Poolbeg Pharma has been analysing flu human challenge trials data since March 2022. Poolbeg Pharma, an Irish biopharmaceutical company that focuses on

Biopharmaceutical company Poolbeg Pharma said it has successfully used artificial intelligence to identify a number of potential drug targets in the treatment of influenza, dramatically reducing the time taken to

Poolbeg Pharma, a clinical-stage biopharmaceutical company focusing on infectious and other prevalent diseases with a high unmet medical need, has announced a significant breakthrough in its influenza Artificial Intelligence programme

Poolbeg Pharma has identified multiple new drug targets for the treatment of influenza. This marks a “significant” breakthrough in its artificial intelligence programme with medtech company CytoReason. Poolbeg has been